These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
30. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. Yamauchi T; Hoki T; Oba T; Saito H; Attwood K; Sabel MS; Chang AE; Odunsi K; Ito F JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32255766 [TBL] [Abstract][Full Text] [Related]
31. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H Front Immunol; 2021; 12():793831. PubMed ID: 34987517 [TBL] [Abstract][Full Text] [Related]
33. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner. He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555 [TBL] [Abstract][Full Text] [Related]
34. Type 17 immunity promotes the exhaustion of CD8 Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800 [TBL] [Abstract][Full Text] [Related]
36. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8 Frey AB Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354 [TBL] [Abstract][Full Text] [Related]
37. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072 [TBL] [Abstract][Full Text] [Related]
38. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. Reiser J; Banerjee A J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056 [TBL] [Abstract][Full Text] [Related]
39. TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. Menger L; Sledzinska A; Bergerhoff K; Vargas FA; Smith J; Poirot L; Pule M; Hererro J; Peggs KS; Quezada SA Cancer Res; 2016 Apr; 76(8):2087-93. PubMed ID: 27197251 [TBL] [Abstract][Full Text] [Related]
40. Remodeling of the tumor microenvironment via disrupting Blimp1 Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]